A critical question for men with favorable intermediate-risk prostate cancer (based primarily on a Gleason score of 3 + 4 = 7) can often be, “How safe would it be for me to go on active surveillance for a while after initial diagnosis?” Read the article here.
Active surveillance in men with Gleason 3 + 4 = 7 prostate cancer at diagnosis Read More »
March 2018 Awareness Night How clinical trials have changed prostate cancer care Dr. Andrew Loblaw BSc MD MSc FRCPC CIP Clinician Scientist , Ontario Association of Radiation OncologyStaff Radiation Oncologist & Clinician Scientist, Sunnybrook Health Sciences Centre Scientist, Sunnybrook Research Institute Fellow, American Society of Clinical Oncology (ASCO) Co-Chair, GU group for Cancer Care Ontario’s Program in Evidence-Based Care Previous Co-Chair, ASCO’s Genitourinary Advisory Group Professor, Department of Radiation Oncology at University of Toronto Professor,The Institute of Health Policy, Management and Evaluation (IHPME) CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 66:27 minutes
Video: “How clinical trials have changed prostate cancer care” Read More »
A substantial proportion of men with low-risk prostate cancer can safely be followed with a de-intensified active surveillance protocol. Read the article here.
When can active surveillance be less active? Read More »
For men with metastatic prostate cancer there is no survival advantage for aggressive therapy over conservative androgen deprivation therapy only, according to a study. Read the article here.
No Benefit for Aggressive Therapy in Metastatic Prostate Cancer Read More »
A greater than 90-day delay from prostate biopsy to radical prostatectomy for localized prostate cancer may increase the risk of biochemical recurrence of disease, according to study findings. Read the article here.
Biopsy-to-RP Delay May Up Prostate Cancer Recurrence Risk Read More »
A new study shows that a mix of different treatments, or a “multimodal” approach to prostate cancer therapy, lengthens survival in men who have this diagnosis. Read the article here.
A mix of treatments may extend life for men with aggressive prostate cancer Read More »
A drug used to treat enlarged prostate or hair loss in men has been shown to have a long-term protective effect against prostate cancer. Read the article here.
Finasteride can reduce prostate cancer risk long term Read More »
Repeat biopsy before radical prostatectomy impairs early continence after surgery. However, erectile function recovery and mid‐term to long‐term continence are not affected. These data support the current trend towards active surveillance and delayed local treatment in patients with low‐ to intermediate‐risk prostate cancer. Read the article here.
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. Read the article here.
Higher doses of radiation don’t improve survival in prostate cancer Read More »
Brachytherapy-based radiotherapy and radical prostatectomy produced similar survival results for men with high-risk, localized prostate cancer, according to findings published in the Journal of Clinical Oncology. Read the article here.